Literature DB >> 16979761

Mantoux Test as a model for a secondary immune response in humans.

Milica Vukmanovic-Stejic1, John R Reed, Katie E Lacy, Malcolm H A Rustin, Arne N Akbar.   

Abstract

The Mantoux Test (MT) is a classical delayed-type hypersensitivity (DTH) response to the intradermal injection of tuberculin purified protein derivative (PPD). It represents a cutaneous T cell mediated memory recall immune response. The test is typically used to determine immunity to tuberculosis in humans and positive reactions develop in individuals previously exposed to Mycobacterium tuberculosis, and those immunised with the Bacillus of Calmette and Guérin (BCG) vaccine. In view of its relative accessibility human skin represents a convenient tissue for the investigation of human immune responses. Using the MT, we have been able to determine that significant cellular proliferation and clonal expansion occur at the site of antigen deposition in the skin. Furthermore, cells undergoing proliferation in the skin also undergo accelerated differentiation. Taken together with other studies, in humans and in mice, these observations shed new light on the importance of the microenvironment at the site of the immune response for the proliferation and differentiation of memory T cells.

Entities:  

Mesh:

Year:  2006        PMID: 16979761     DOI: 10.1016/j.imlet.2006.08.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  22 in total

1.  TNF-alpha antagonist therapy modify the tuberculin skin test response.

Authors:  Tulin Cagatay; Zeki Kilicaslan; Penbe Cagatay; Munevver Mertsoylu; Ziya Gulbaran; Reyhan Yildiz; Leyla Pur; Sevil Kamali; Ahmet Gul
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

2.  The growing feather as a dermal test site: Comparison of leukocyte profiles during the response to Mycobacterium butyricum in growing feathers, wattles, and wing webs.

Authors:  G F Erf; I R Ramachandran
Journal:  Poult Sci       Date:  2016-04-14       Impact factor: 3.352

3.  Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.

Authors:  Alexandra Belson; Tim Schmidt; Disala Fernando; Kelly Hardes; Nicola Scott; Sara Brett; Deborah Clark; João Joaquim Oliveira; Bill Davis; Simon McHugh; John Stone
Journal:  Inflamm Res       Date:  2016-03-11       Impact factor: 4.575

4.  Synergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosy.

Authors:  R M Oliveira; E M Hungria; A de Araújo Freitas; A L O M de Sousa; M B Costa; S G Reed; M S Duthie; M M A Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-12       Impact factor: 3.267

5.  Tuberculin skin test reactivity is dependent on host genetic background in Colombian tuberculosis household contacts.

Authors:  Aurélie Cobat; Luis F Barrera; Hanna Henao; Patricia Arbeláez; Laurent Abel; Luis F García; Erwin Schurr; Alexandre Alcaïs
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

6.  Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection.

Authors:  Hongliang Yang; JoLynn Troudt; Ajay Grover; Kimberly Arnett; Megan Lucas; Yun Sang Cho; Helle Bielefeldt-Ohmann; Jennifer Taylor; Angelo Izzo; Karen M Dobos
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

7.  Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys.

Authors:  K G Haanstra; J Endell; D Estévâo; I Kondova; M Jonker
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

8.  Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy.

Authors:  Ilhan Sezer; Hilal Kocabas; Meltem Alkan Melikoglu; Mehmet Arman
Journal:  Clin Rheumatol       Date:  2008-08-08       Impact factor: 2.980

9.  Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.

Authors:  Tulin Cagatay; Munevver Aydin; Sule Sunmez; Penbe Cagatay; Ziya Gulbaran; Ahmet Gul; Bahar Artim; Zeki Kilicaslan
Journal:  Rheumatol Int       Date:  2009-10-21       Impact factor: 2.631

10.  Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis.

Authors:  Aurelie Cobat; Caroline J Gallant; Leah Simkin; Gillian F Black; Kim Stanley; Jane Hughes; T Mark Doherty; Willem A Hanekom; Brian Eley; Jean-Philippe Jaïs; Anne Boland-Auge; Paul van Helden; Jean-Laurent Casanova; Laurent Abel; Eileen G Hoal; Erwin Schurr; Alexandre Alcaïs
Journal:  J Exp Med       Date:  2009-11-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.